Is there a positive effect on the financial returns of a company active in developing countries?

In the past, investment in Index Countries was not the most attractive option due to risky operating environments. Today, however, rapid economic growth, improving healthcare systems, changing lifestyles, population growth, along with lower R&D and manufacturing costs, signal great potential for meaningful pharmaceutical industry growth opportunities in these regions. According to IMS Health Inc., emerging economies represented only 12% of growth in the pharmaceutical sector in 2001; in 2009, however, they are expected to represent 73% of global growth.